Earnings summaries and quarterly performance for Acadia Healthcare Company.
Executive leadership at Acadia Healthcare Company.
Board of directors at Acadia Healthcare Company.
EP
E. Perot Bissell
Detailed
Director
JR
Jason R. Bernhard
Detailed
Director
MJ
Michael J. Fucci
Detailed
Director
PA
Patrice A. Harris, M.D., M.A.
Detailed
Director
RD
R. David Kelly
Detailed
Director
RB
Reeve B. Waud
Detailed
Chairman of the Board
VB
Vicky B. Gregg
Detailed
Director
WD
Wade D. Miquelon
Detailed
Director
WF
William F. Grieco
Detailed
Director
Research analysts who have asked questions during Acadia Healthcare Company earnings calls.
Andrew Mok
Barclays
4 questions for ACHC
Also covers: ADUS, AGL, ALHC +21 more
Brian Tanquilut
Jefferies
4 questions for ACHC
Also covers: ADUS, AHCO, AMED +29 more
AR
Albert Rice
UBS
3 questions for ACHC
Also covers: AMED, AMN, BTSG +20 more
Benjamin Hendrix
RBC Capital Markets
3 questions for ACHC
Also covers: ADUS, AHCO, AMED +25 more
BM
Benjamin Mayo
Leerink Partners
3 questions for ACHC
Also covers: AGL, AMED, ARDT +10 more
JR
John Ransom
Raymond James
3 questions for ACHC
Also covers: ADUS, ALHC, AMED +11 more
MG
Matthew Gillmor
KeyCorp
3 questions for ACHC
Also covers: ADUS, ALHC, ARDT +11 more
JG
Joanna Gajuk
Bank of America
2 questions for ACHC
Also covers: ADUS, AGL, ALHC +21 more
PC
Pito Chickering
Deutsche Bank
2 questions for ACHC
Also covers: AHCO, AVAH, BAX +18 more
SF
Scott Fidel
Stephens Inc.
2 questions for ACHC
Also covers: ADUS, ALHC, AMED +17 more
AR
A.J. Rice
UBS Group AG
1 question for ACHC
Also covers: AMED, AMN, BTSG +20 more
GI
Gabrielle Ingoglia
Cantor Fitzgerald
1 question for ACHC
Also covers: DCGO, HCAT, TBRG +1 more
Jason Cassorla
Guggenheim Partners
1 question for ACHC
Also covers: ARDT, CI, CYH +8 more
JD
Joanna Dudjuk
Bank of America
1 question for ACHC
Raj Kumar
Stephens
1 question for ACHC
Also covers: ADUS, ARDT, AVAH +7 more
RL
Ryan Langston
TD Cowen
1 question for ACHC
Also covers: ADUS, AGL, ALHC +15 more
Sarah James
Cantor Fitzgerald
1 question for ACHC
Also covers: AMED, CI, CNC +15 more
Whit Mayo
Leerink Partners
1 question for ACHC
Also covers: AHCO, ALHC, AMED +11 more
Recent press releases and 8-K filings for ACHC.
Acadia Healthcare Reiterates 2025 Guidance and Outlines 2026 Strategy
ACHC
Guidance Update
New Projects/Investments
Demand Weakening
- Acadia Healthcare reiterated its 2025 guidance, expecting revenue of $3.28-$3.3 billion, adjusted EBITDA of $601-$611 million, and adjusted EPS of $1.94 to $2.04. The company faced a difficult financial year in 2025 due to higher professional liability costs, softer volume trends in Medicaid-heavy markets, and increased pressure on revenue yield.
- The company anticipates significant future growth from its new facilities, with over 2,500 new beds added in the past three years and 500-700 more planned for 2026. These investments are projected to unlock at least $150 million of future EBITDA at maturity, or over $200 million incrementally when accounting for startup losses.
- Acadia expects a material reduction in CapEx in 2026 by at least $300 million from its $610-$630 million 2025 guidance, with further declines in 2027, leading to the generation of positive free cash flow in 2026. Key headwinds for 2026 include continued Medicaid volume softness and payer pressures, while tailwinds include ramping contributions from new beds and expanded supplemental payments.
2 days ago
Acadia Healthcare Reiterates 2025 Guidance and Outlines 2026 Outlook
ACHC
Guidance Update
New Projects/Investments
Demand Weakening
- Acadia Healthcare reiterated its 2025 guidance, expecting revenue of $3.28-$3.3 billion, adjusted EBITDA of $601-$611 million, and adjusted EPS of $1.94 to $2.04.
- The company reported a difficult financial performance year in 2025, primarily due to higher professional liability costs, softer-than-anticipated volume growth, and pressure on revenue yield per patient day, which also led to a slower occupancy ramp for new facilities.
- For 2026, Acadia anticipates CapEx to decline by at least $300 million from its 2025 guidance of $610-$630 million, while still adding 500-700 beds, and expects to generate positive free cash flow.
- New facilities opened between 2023 and 2026 represent a significant embedded growth opportunity, with over $200 million in future EBITDA at maturity.
- Key headwinds for 2026 include continued softness in acute care Medicaid volumes and payer-related pressures, with a potential $25-$30 million annual EBITDA impact from a New York Medicaid policy change.
2 days ago
Acadia Healthcare Reiterates 2025 Guidance and Reviews 2025 Performance
ACHC
Guidance Update
Demand Weakening
New Projects/Investments
- Acadia Healthcare reiterated its 2025 guidance, projecting Revenue between $3.28B – $3.30B, Adjusted EBITDA between $601M - $611M, and Adjusted EPS between $1.94 – $2.04.
- The company's 2025 financial results were below expectations, primarily due to increased PLGL litigation costs (-$54M), volume underperformance (~-$30M), and rate pressure (~-$10M).
- In 2025, Acadia added 1,089 new beds and closed 382 beds, resulting in 707 net beds added across Acute, Specialty, and RTC facilities.
- For 2026, Acadia anticipates an improvement in free cash flow driven by a planned reduction in capital expenditures by at least $300M.
2 days ago
Acadia Healthcare Reaffirms 2025 Guidance and Outlines 2026 Outlook
ACHC
Guidance Update
New Projects/Investments
Demand Weakening
- Acadia Healthcare reiterated its 2025 guidance for revenue of $3.28-$3.3 billion, adjusted EBITDA of $601-$611 million, and adjusted EPS of $1.94-$2.04, despite a difficult 2025 financial performance driven by higher professional liability costs, softer volumes, and payer pressure.
- The company expects CapEx to decline by at least $300 million in 2026 (from $610-$630 million in 2025) while adding 500-700 new beds, anticipating meaningful free cash flow generation and an embedded growth opportunity of at least $150 million in future EBITDA from over 2,500 new beds opened since 2023.
- Key headwinds for 2026 include continued softness in acute care Medicaid volumes, ongoing payer pressures, an estimated $25-$30 million annual EBITDA impact from New York's out-of-state Medicaid policy, and the non-recurring $28.5 million benefit from Tennessee's 2024 supplemental payment recorded in Q2 2025.
2 days ago
Acadia Healthcare Reaffirms 2025 Financial Guidance at J.P. Morgan Healthcare Conference
ACHC
Guidance Update
- Acadia Healthcare Company, Inc. (ACHC) representatives are participating in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with a live webcast of their presentation available.
- Management is reaffirming its 2025 financial guidance for revenue, Adjusted EBITDA, and Adjusted earnings per share, which was previously provided in its November 5, 2025 earnings release and updated by its December 2, 2025 press release.
- The reaffirmed 2025 guidance includes revenue in the range of $3.28 billion to $3.30 billion, Adjusted EBITDA in the range of $601 million to $611 million, and Adjusted earnings per share in the range of $1.94 to $2.04.
- The company noted potential reductions in payments from government and commercial payors due to significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (OBBBA), enacted on July 4, 2025.
3 days ago
Acadia Healthcare Lowers 2025 EPS Guidance Amid Rising Liability Costs
ACHC
Guidance Update
Profit Warning
Legal Proceedings
- Acadia Healthcare (ACHC) has revised its 2025 financial guidance downward, now expecting adjusted EPS between $1.94 and $2.04 and adjusted EBITDA in the range of $601 million to $611 million.
- This revision is primarily due to a significant increase in professional and general liability (PLGL) expenses, driven by higher settlement costs for claims related to prior policy years and increased claim frequency for the 2025 policy year, which exceeded expectations after an actuarial review.
- The company's financial distress indicators include an Altman Z-Score of 1.07, placing it in the financial distress zone, and a price-to-book ratio of 0.48, near a 10-year low, underscoring concerns about financial stability.
Dec 2, 2025, 10:46 PM
Acadia Healthcare Updates PLGL Reserves and Lowers 2025 Guidance
ACHC
Guidance Update
Profit Warning
Legal Proceedings
- Acadia Healthcare Company, Inc. (ACHC) has lowered its full-year 2025 guidance for Adjusted EBITDA and Adjusted EPS due to an increase in professional and general liability (PLGL) expenses identified during an annual actuarial review.
- The company now expects full-year 2025 Adjusted EBITDA in the range of $601 million to $611 million (down from $650 million to $660 million) and Adjusted EPS of $1.94 to $2.04 (down from $2.35 to $2.45), reflecting an incremental $49 million in PLGL expense and a $0.41 reduction in EPS.
- The projected 2025 PLGL expense is approximately $116 million, a significant increase from $54 million in 2024, driven by factors including a 168% increase in claim frequency during the 2025 policy year and higher expected settlement costs.
- The net PLGL liability at year-end 2025 is expected to rise to $145 million to $165 million, compared to $78 million on December 31, 2024.
Dec 2, 2025, 9:10 PM
Acadia Healthcare Discusses Litigation Settlement, 2025 Performance, and 2026 Outlook
ACHC
Legal Proceedings
Guidance Update
CFO Change
- Acadia Healthcare has agreed to settle previously disclosed shareholder litigation for $179 million, which will be funded by approximately $30 million in anticipated insurance proceeds, with the remainder from cash on hand and existing line of credit. This settlement is expected to increase net leverage modestly from 3.4 times to approximately 3.65 times.
- The company's results through the third quarter of 2025 were modestly below expectations, leading to updated guidance, with the fourth quarter reflecting headwinds such as volume softness and rate pressures. However, management does not believe Q4 2025 should be viewed as a new baseline for 2026, anticipating declining startup losses, improved margin mix from facility closures, and ramping contributions from recent bed additions.
- Acadia has added 1,700 new beds in 2024 and through the first three quarters of 2025, with 632 beds entering the same-store calculation in Q1 2026, and plans to reduce CapEx by $300 million in 2026. The company also closed five underperforming facilities in 2025 as part of portfolio optimization.
- The company anticipates at least $22 million of annual EBITDA improvements from pending supplemental payment programs, which could be recognized in Q4 2025 or early 2026.
- The labor market is showing stabilization, with base wage inflation ticking down slightly in Q3 2025 and improved employee retention for six consecutive quarters.
Nov 11, 2025, 7:45 PM
Acadia Healthcare Reports Q3 2025 Results and Updates Full-Year Guidance
ACHC
Guidance Update
Demand Weakening
Management Change
- Acadia Healthcare reported Q3 2025 revenue of $851.6 million, a 4.4% increase year-over-year, and Adjusted EBITDA of $173 million, compared to $194.3 million in the prior year period.
- The company reduced its full-year 2025 guidance for revenue to $3.28 billion-$3.3 billion, Adjusted EBITDA to $650 million-$660 million, and Adjusted EPS to $2.35-$2.45.
- This revised outlook is attributed to softer-than-expected volumes in its Medicaid business, rate pressure, increased bad debts and denials, and higher professional and general liability expense.
- Acadia is realigning capital spending priorities, projecting 2026 CapEx to be at least $300 million lower than the revised 2025 CapEx guidance of $610 million-$630 million, and expects to generate positive adjusted free cash flow for the full year 2026.
- Todd Young recently joined as Chief Financial Officer, and Nasser Khan is stepping down as Chief Operating Officer.
Nov 6, 2025, 2:00 PM
Acadia Healthcare Reports Q3 2025 Results, Lowers Full-Year Guidance, and Announces CFO Change
ACHC
Earnings
Guidance Update
Management Change
Demand Weakening
- Acadia Healthcare reported Q3 2025 revenue of $851.6 million, a 4.4% increase over the prior year period, and Adjusted EBITDA of $173 million, compared to $194.3 million in Q3 2024.
- The company revised its full-year 2025 guidance, lowering revenue to $3.28 billion - $3.3 billion and Adjusted EBITDA to $650 million - $660 million, primarily due to softer-than-expected volumes in its Medicaid business and incremental headwinds from rates and expenses. Adjusted EPS guidance was also revised to $2.35 - $2.45.
- Acadia Healthcare announced a realignment of capital spending priorities, with 2026 CapEx expected to be at least $300 million lower than the revised 2025 guidance of $610 million - $630 million, aiming to generate positive adjusted free cash flow for the full year 2026.
- Todd Young was appointed as the new Chief Financial Officer, and the company made a decision to cease operations at five facilities that no longer aligned with strategic priorities or demonstrated persistent underperformance.
Nov 6, 2025, 2:00 PM
Quarterly earnings call transcripts for Acadia Healthcare Company.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more